SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study

Peter Polzik^1, Olav Grøndal^1, Juliette Tavenier^2, Martin B. Madsen^3, Ove Andersen^2,4, Morten Hedetoft^3 & Ole Hyldegaard^1

Necrotizing soft tissue infections (NSTIs) have a 90-day mortality rate of 18–22%. Tools are needed for estimating the prognosis and severity of NSTI upon admission. We evaluated soluble urokinase-type plasminogen activator receptor (suPAR) levels at admission as a prognostic marker of NSTI severity and mortality. In a prospective, observational cohort study, suPAR was measured in 200 NSTI patients. We compared admission suPAR levels in survivors and non-survivors, patients with septic shock and non-shock, amputation and non-amputation, correlations with Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) score. Admission suPAR levels were higher in septic shock vs. non-septic shock patients (9.2 vs. 5.8 ng/mL, p-value < 0.001) and non-survivors vs. survivors (11 vs. 6.1 ng/mL, p-value < 0.001) and correlated with SAPS II (r = 0.52, p < 0.001) and SOFA score (r = 0.64, p < 0.001). Elevated suPAR upon admission was associated with 90-day mortality (log-rank test p < 0.001), however not after adjustment for age, sex, and SOFA score. The AUC for suPAR and 90-day mortality was 0.77. We found that suPAR is a promising candidate for prognosis and severity in patients with NSTI.

Necrotizing soft-tissue infections (NSTIs) are characterized by rapidly progressing soft tissue inflammation and necrosis, and can cause septic shock, multiple organ failure and death. Patients can become mortally infected in hours. Mortality is 18–23%, and patients with NSTI can require amputation and prolonged rehabilitation. NSTIs are rare, with an annual incidence of 1.69 to 4 per 100,000 per year, but awareness is critical due to their high mortality and complication rates.

We currently lack the proper tools to rapidly evaluate the severity and prognosis of NSTI. Furthermore, the current consensus is that time to initial surgery is critical and that it should be as soon as possible. A tool for quickly assessing the risk of mortality for a suspected NSTI patient could minimize the delay to primary surgery.

We examined the role of soluble urokinase-type plasminogen activator receptor (suPAR) in patients with NSTI. SuPAR is the soluble form of urokinase plasminogen activator receptor (uPAR) after it is cleaved from the cell membrane, and reflects the activity of the immune system. Elevated suPAR levels are associated with the risk of currently having or developing acute and chronic conditions including cancer, diabetes mellitus, cardiovascular disease, and acute exacerbations of chronic obstructive lung disease, severe sepsis and septic shock, multiple organ failure as well as predicting mortality during these diseases. High suPAR is also associated with mortality in patients with bacteremia, bacterial meningitis, systemic inflammatory response syndrome and sepsis.

^1Department of Anesthesiology, Center of Head and Orthopedics, Copenhagen University Hospital (Rigshospitalet), Copenhagen Ø, Denmark. ^2Clinical Research Center, Copenhagen University Hospital (Hvidovre), Hvidovre, Denmark. ^3Department of Intensive Care, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark. ^4The Emergency Department, Copenhagen University Hospital (Hvidovre), Hvidovre, Denmark. ^5Hyperbaric Medicine Center, Department of Anesthesiology, Center of Head and Orthopedics, University Hospital of Copenhagen (Rigshospitalet), Copenhagen, Denmark. Correspondence and requests for materials should be addressed to P.P. (email: pyotropolzik@gmail.com)
We aimed to evaluate the use of admission suPAR levels as a possible tool to assess NSTI severity and prognosis. We hypothesized that suPAR levels were elevated in survivors vs. non-survivors, in patients with septic shock vs. non-septic shock and in patients who were amputated vs. not amputated. Furthermore, we theorized that in patients with NSTI stratified into no sepsis, sepsis and septic shock as defined by the new Sepsis-3 standardized criteria\textsuperscript{20}, plasma suPAR correlates with NSTI patients’ clinical condition as assessed by the Simplified Acute Physiology Score II (SAPS II) and by the Sequential Organ Failure Assessment (SOFA) score.

**Methods**

**Study design.** This study was a prospective, observational cohort study of patients with NSTI admitted to Copenhagen University Hospital (CUH), Rigshospitalet. The study was a sub-study of the INFECT project (clinicaltrials.gov; NCT01790698). All patients with presumed NSTI were screened and enrolled after diagnosis was confirmed by surgery. Patients used for this study were included between February 2013 and February 2016.

**Patient inclusion criteria were.**

1. NSTI based on surgical findings (necrotic or deliquescent soft tissue with widespread undermining of the surrounding tissue)
2. Age \( \geq 18 \) years
3. Operated for NSTI at Rigshospitalet.

**Patient exclusion criteria were.**

1. Diagnosed as non-NSTI peroperatively.

An arterial or venous blood sample from each patient was collected into ethylenediaminetetraacetic acid (EDTA) sample tubes four times: once upon admission to CUH (baseline) and each of the following three days, between 08:00 and 12:00. The anticoagulated blood was put on ice until centrifugation (within 40 minutes of collection, at 3500 rpm for ten minutes). The supernatant (plasma) was stored in 1 mL vials at \(-80 \) °C until analysis.

**Patient management.** All patients with NSTI were treated using a standardized protocol consisting of frequent surgical evaluation and debridement as necessary, intensive care therapy, immunoglobulin therapy, broad-spectrum antibiotics in the form of meropenem, clindamycin and ciprofloxacin and adjuvant hyperbaric oxygen therapy.

**Data collection.** Clinical data from the first seven days in the ICU was entered into an electronic case report form. Vital status and time of death, if relevant, were obtained from the Danish Civil Registry.

**SuPAR levels.** Blood samples were analyzed at the Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark. The analysts conducting the suPAR analysis were blinded to patient type and outcome. Plasma levels of suPAR were measured using the enzyme-linked immunosorbent assay suPARnostic\textsuperscript{6} according to the manufacturer’s instructions (ViroGates A/S, Birkerød, Denmark). The standard curve range for the assay was 1.0–17.8 ng/mL, samples above the standard range were diluted appropriately and re-measured. All samples from one patient were measured on the same plate, and all the samples were measured in duplicates. The intra-assay variance was 3.0%.

**Outcomes.** The primary outcome was the association between plasma suPAR levels measured upon admission in NSTI patients with and without septic shock, and NSTI day-90 mortality, SAPS II and SOFA scores. The stratification into septic shock and non-shock was relevant due to the expected higher mortality rate in septic shock patients.

In secondary analyses we compared suPAR levels at admission and during the following three days in the ICU between non-shock vs. shock patients, survivors vs. non-survivors and amputations vs. no amputations. Additionally, we calculated differences in SOFA and SAPS II levels between survivors and non-survivors, and patients with septic shock and non-shock. Patients were followed from admission to either the end of follow up (January 2017) or death, whichever came first.

**Sample size.** To the best of our knowledge, suPAR levels during NSTI have never previously been examined. The sample size calculation was based on a previous study concerning the correlation between suPAR and sepsis\textsuperscript{15}. Significant correlations between suPAR, sepsis and mortality were also found in a different study of 132 patients\textsuperscript{16}. We therefore wanted to include at least 150 patients with NSTI during this study\textsuperscript{21}.

**Statistics.** Data are reported as means with 95% confidence intervals (CI) in parentheses. All following test assumptions were met. Continuous data were compared using Wilcoxon rank-sum tests. Correlations were assessed using Spearman’s rank test. Categorical data are reported as absolute numbers, with the proportion in parentheses, and comparisons done using the Chi-squared test.

Receiver operating characteristic (ROC) curve analysis and areas under the curve (AUC) were applied to determine suPAR’s accuracy as a marker of severity and mortality in patients with NSTI. We constructed Kaplan-Meier curves with log-rank tests for survival data. Cox multiple regression analysis was used to assess mortality hazard ratios. A two-tailed p-value below 0.05 was considered statistically significant.
Statistical analysis was conducted using R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. R version 3.3.2 and RStudio 1.0.136.

**Ethics.** The study was conducted in accordance with the principles of the Declaration of Helsinki. The Regional Health Research Ethics Committee (RHREC) and the Danish Data Protection Agency (DDPA) approved the study (RHREC document number: H-16021845; DDPA j. no.: RH-2016-199). Written informed consent was obtained from the patients or their legal surrogates. The study is registered at clinicaltrials.gov (NCT03147352). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed in the preparation of this manuscript22.

**Results**

**Baseline characteristics.** A total of 245 patients were screened for eligibility. Of these, 200 were included (Fig. 1).

There were no differences in any of the baseline characteristics of this cohort, as published previously by our study group23,24. Our cohort included an additional 40 patients, as compared to the cohort previously published. The median age was 61 years (range 53–69) and had a 60/40 male-to-female ratio. See Table 1 for baseline characteristics, (SAPS II and SOFA score values, clinical severity, mortality rates).

19 patients (10%) either died (n = 15) or were discharged (n = 4) prior to Day 4 blood sampling and whose Day 4 blood samples were therefore missing in the analyses of biomarker levels and were dealt with by pairwise deletion.

Seven patients (3.5%) had missing SAPS II and SOFA score values, exclusively due to missing bilirubin measurements, and were excluded from the multivariate analysis. Follow-up was 99.5% complete, with mortality data only missing for one patient: a tourist who left the country permanently 18 days after initial admittance to CUH.

**SupAR levels and NSTI severity and outcome.** Admission suPAR levels were higher in non-survivors (11 (95% CI, 9.1–13) vs. 6.1 (95% CI, 5.5–6.7) ng/mL, p < 0.001) (Table 1). Admission suPAR levels were also higher for septic shock patients (9.2 (8–10.4) vs. 5.8 (5.1–6.6) ng/mL, p < 0.001) (Table 1).

SuPAR levels during the three days following admission in the ICU were significantly different for each separate day for survivors vs. non-survivors and shock vs. non-shock groups (Fig. 2). For the amputation vs. non-amputation groups, supAR levels were significantly different for the groups in total (p < 0.01) as well as at admission (p = 0.008), and Day 2, 3 and 4 (p-values = 0.02) (Fig. 2).

Moreover, suPAR levels were correlated with both SAPS II (r = 0.52 (95% CI, 0.43–0.63), p-value < 0.001) and SOFA score (r = 0.64 (95% CI, 0.53–0.7), p < 0.001).

**SuPAR levels and 90-day mortality.** Elevated admission suPAR levels were significantly associated with 90-day mortality in the Kaplan-Meier analysis (log rank test p < 0.001) (Fig. 4). However, after adjustment for
In ROC curve analyses, the AUC for suPAR for predicting 90-day mortality was 0.77 (0.7–0.85) (Fig. 3). The optimal suPAR cutoff value for predicting 90-day mortality (found via the suPAR ROC curve seen in Fig. 3) was 7.4 ng/mL. This suPAR level could also differentiate patients into groups at lower or higher risk of amputation (10% vs. 26%) (Table 1).

We also compared suPAR's AUC to the accuracy of SAPS II and the SOFA score in predicting mortality. SAPS II AUC was 0.87 (0.81–0.92), while SOFA score (day 1) had an AUC of 0.82 (0.74–0.9). Adding all three (SAPS II, SOFA score and suPAR) to the model did not improve it compared to SAPS II alone (AUC = 0.87 (0.81–0.92)).

**Discussion**

Admission suPAR levels were higher in NSTI patients with septic shock, in patients who were amputated and in patients who died before day 90. Admission suPAR levels were also correlated with SAPS II and the SOFA score day 1. The ROC-AUC for suPAR and mortality was high, though the ROC-AUC for SAPS II and SOFA score day 1 was higher. SuPAR was not associated with 90-mortality when adjusted for age, sex, and SOFA score day 1. Our results show that admission suPAR can indeed approximate NSTI severity and mortality.

Age and chronic diseases have been shown to correlate with suPAR levels. However, in many studies, suPAR is still associated with mortality after adjustment for age and chronic diseases. We wanted to determine whether suPAR could predict mortality in NSTI patients. Our data, however, showed that suPAR was not independently prognostic for NSTI mortality.

SuPAR has been reported as being active in many different areas of host defense: plasminogen activation, inflammation, cell adhesion, mobilization, migration and proliferation, as well as chemotaxis. The high prognostic accuracy of suPAR has been ascribed to its inhibition of neutrophil phagocytosis, thereby possibly directly reflecting immune system impairment. This could explain its superiority over C-reactive protein and procalcitonin, which are only surrogate markers of inflammation.

SuPAR levels were higher in patients who underwent amputation. This further strengthens the potential of using suPAR as a “warning bell” for medical doctors and surgeons who encounter patients with possible NSTI. Due to the relative rarity of NSTIs, it is critical that physicians who have limited experience with these infections can rapidly assess the prognosis of these patients.

| N (%) | Mortality, N (%) | SAPS II (95% CI) | SOFA (95% CI) |
|-------|-----------------|-----------------|---------------|
| Died within 90 days | | | |
| Yes | 43 (22) | 62 (58–67) | 10.9 (9.9–11.9) |
| No | 157 (78) | 41 (39–43) | 7.2 (6.7–7.7) |
| Septic shock | | | |
| Yes | 79 (40) | 29 (37) | 52 (49–56) | 10 (9.4–10.7) |
| No | 121 (60) | 14 (12) | 42 (39–44) | 6.7 (6.1–7.2) |

| N (%) | suPAR (ng/mL) | 95% CI | P-value |
|-------|---------------|--------|---------|
| Yes | 43 (22) | 11 | 7.8–14.2 | <0.001 |
| No | 157 (78) | 6.1 | 2.9–9.3 | <0.001 |
| Septic shock | | | |
| Yes | 79 (40) | 9.2 | 7–11.2 | |
| No | 121 (60) | 5.8 | 3.6–8 | |

| N (%) | suPAR (ng/mL) | 95% CI | P-value |
|-------|---------------|--------|---------|
| No amputation | | | |
| 118 (90%) | 13 (10%) | 131 | |
| suPAR ≤ 7.4 ng/mL | | | |
| 51 (74%) | 18 (26%) | 69 | |
| suPAR ≥ 7.4 ng/mL | | | |

Table 1. Differences in admission SAPS II and SOFA score, plasma suPAR levels between survivors and non-survivors, septic shock and non-septic shock patients and differences in amputation rates in high vs. low suPAR (above or below 7.4 ng/mL) NSTI patients. Data are means (95% CI) or numbers (%). SAPS II Simplified Acute Physiology Score II. SOFA Sequential Organ Failure Score. suPAR soluble urokinase-type plasminogen activator receptor. NSTI necrotizing soft-tissue infections. Pearson’s Chi-squared test with Yate’s continuity correction, $X^2 = 7.8$, p-value = 0.005. Optimal cutoff for predicting Day-90 mortality of 7.4 ng/mL was found via the suPAR ROC curve. Welch’s t-test, p-value < 0.001.
The correlation of suPAR with SAPS II and the SOFA score agrees with previous research\(^{16,25}\). Our ROC-AUC for mortality and suPAR (AUC = 0.78) is the same as in a previous report in patients with systemic inflammatory response syndrome (AUC = 0.8)\(^{18}\). While SAPS II was better than suPAR at predicting mortality in our NSTI patient cohort, it cannot be used upon admission. SAPS II relies on 17 variables, some of which are time-consuming to acquire, expensive and require manual input from medical personnel\(^{33}\). In addition, these variables are not always available for all patients. Furthermore, the SAPS II score is only applicable after 24 hours of admission, thereby invalidating it for use in admission triage. The SAPS II score has been updated to SAPS III, which can be calculated within 1 hour of ICU admission but requires even more resources and variables to calculate, many of which may be missing upon admission. SuPAR, on the other hand, requires only analysis of a single blood sample, and can easily be done immediately upon admission. SuPAR levels can be available within 30 minutes of blood sampling, using a quantitative point of care prognostic triage test.

C-reactive protein, procalcitonin and other standard biochemical marker levels have been shown to have poor association with mortality in NSTI patients\(^{23}\). SuPAR has been shown to have superior prognostic value in other ICU patients compared to standard biomarkers as well as having minimal circadian variations\(^{19}\). Our results of
suPAR levels above 12 ng/mL being an optimal cut-off point for mortality prognosis are in line with other studies reviewed\(^3\). Many of the studies we refer to conclude by describing suPAR’s potential as a triage marker, including a systematic review of suPAR’s usefulness during infections\(^1\).

The strengths of our study include the prospective design and that it is the first to investigate the prognostic value of suPAR in NSTI patients. The predefined study and analysis plan is a major strength\(^2\). Another strength is the inclusion of all NSTI patients who were transferred to our tertiary care hospital during the study period, minimizing selection bias. Follow-up rates were very high, negating attrition bias. The simple and limited inclusion and exclusion criteria increase the chance of the study cohort reflecting the standard NSTI patient. These factors strengthen the study’s external validity. Furthermore, blood sampling and clinical data acquisition was standardized and conducted using predefined standard operational procedures. The staff responsible for suPAR analysis was blinded regarding study purpose and patient outcome.

Our study has several limitations. As with other observational studies, unknown confounders are difficult to control for. NSTI patients are a heterogeneous group, and suPAR levels could be influenced by unknown factors in these patients. However, there were no differences in any of the baseline characteristics that we had access to. It is also conceivable that any NSTI patients who were not transferred to CUH in time before they became too critically ill to transport escaped inclusion in our study, thus possibly skewing our results through selection bias. In the present report and in line with the statistical analysis plan we did not correlate surgical findings with suPAR levels. Although of interest, one should bear in mind that surgical findings are based on a predominantly subjective, clinical description of the tissue visualized during the procedure and often not subject to a systematic, histological analysis of tissue destruction nor use of objectively verifiable measurements. We acknowledge this as a limitation in present report although it does not change the overall conclusion when using suPAR as a potential clinical marker in NSTI triage. A final limitation is that we only gathered blood samples during the first three days of admission to CUH, meaning we cannot follow the long-term suPAR levels after appropriate treatment was initiated. We however see that suPAR levels stayed remarkably steady for the first few days considering the immediate initiation of treatment upon admission to CUH (Fig. 2).

When taken in conjunction with our present study, we believe that suPAR thus shows great potential as a routine clinical marker for NSTI triage upon admission. We suggest that the next step in verification could be a randomized-controlled trial, where suPAR is used for NSTI triage in one group to quickly identify the most critically ill NSTI patients and then investigate differences in mortality and other outcomes. We believe that suPAR has the potential to improve patient outcomes while at the same time reducing the costs in time and resources involved with NSTI treatment.

**Conclusion**

We found that plasma suPAR levels are associated with septic shock, amputations and death in patients with NSTI. SuPAR levels correlate with SAPS II and SOFA score. SuPAR is associated with 90-day mortality, but not when adjusted for age, sex, and SOFA score day 1.

**Data Availability**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References

1. Hakkarsaaen, T. W., Kopari, N. M., Pham, T. N. & Evans, H. L. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg 51, 344–362 (2014).
2. Nasaer, U., Steinbakk, M., Blystad, H. & Caugant, D. A. Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: A retrospective cohort study. Eur J Clin Microbiol Infect Dis 35, 1639–1648 (2016).
3. Das, D. K., Baker, M. G. & Venugopal, K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 63, 429–433 (2011).
4. Henry, S. M., Davis, K. A., Morrison, J. J. & Scalea, T. M. Can necrotizing soft tissue infection be reliably diagnosed in the emergency department? Trauma Surg Acute Care Open 3, e00157 (2018).
5. Thuno, M., Macho, B. & Eugen-Olsen, J. suPAR: the molecular crystal ball. Dis Markers 27, 157–172 (2009).
6. Eugen-Olsen, J. et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268, 296–308 (2010).
7. Lyngbaek, S. et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 167, 2904–2911 (2013).
8. Gunus, A. et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis 10, 357–365 (2015).
9. Patrani, M. et al. Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries. Biomarkers 21, 660–664 (2016).
10. Donadello, K. et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29, 144–149 (2014).
11. Casagrande, I. et al. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Intensivmed Notfmed 50, 725–730 (2015).
12. Uusitalo-Seppala, R.
13. Giamarellos-Bourboulis, E. J.
14. Uusitalo-Seppala, R.
15. Wittenhagen, P.
16. Huttunen, R.
17. Ostergaard, C., Benfield, T., Lundgren, J. D. & Eugen-Olsen, J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scandinavian Journal of Infectious Diseases 36, 14–19 (2009).
18. Kofod, K., Eugen-Olsen, J., Petersen, J., Larsen, K. & Andersen, O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 27, 375–383 (2008).
19. Backes, Y. et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38, 1418–1428 (2012).
20. Singer, M. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315, 801–810 (2016).
21. Polzik, P., Johansson, F. I. & Hyldegaard, O. How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark. BMJ Open 7, e017905 (2017).
22. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61, 344–349 (2008).
23. Hansen, M. B. et al. Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study. Crit Care 20, 40 (2016).
24. Hansen, M. B. et al. Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicity, prospective study. Sci Rep 7, 42179 (2017).
25. Koch, A. et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality critically ill patients. Crit Care 15, R63 (2011).
26. Ostervig, R. M. et al. suPAR – A future prognostic biomarker in emergency medicine. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 23, A31 (2015).
27. Moller, H. J. et al. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med 34, 2561–2566 (2006).
28. Mondino, A. & Blasi, F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25, 450–455 (2004).
29. Rijnvede, A. W. et al. Urokinase Receptor Is Necessary for Adequate Host Defense Against Pneumococcal Pneumonia. The Journal of Immunology 168, 3507–3511 (2002).
30. Selleri, C. et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105, 2198–2205 (2005).
31. Park, Y. J., Liu, G., Tsuruta, Y., Lorre, E. & Abraham, E. Participation of the urokinase receptor in neutrophil effococytosis. Blood 114, 860–870 (2009).
32. Wiersinga, W. J. et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 184, 3079–3086 (2010).
33. Le Gall, J.-R. A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study. JAMA: The Journal of the American Medical Association 297, 2957 (1993).
34. Eugen-Olsen, J. & Giamarellos-Bourboulis, E. J. suPAR: The unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents 46(Suppl 1), S33–S34 (2015).

Acknowledgements

The authors would like to thank laboratory technician Arild Ejsing for the suPAR analysis. We would also like to thank the participating patients and their relatives, without whom this study would not have been possible. This study was funded by the Department of Anesthesiology, Center of Head and Orthopedics, Copenhagen University Hospital (Rigshospitalet) and the European Union FP7/2007–2013 (grant number 305340).
Author Contributions
O.H. and O.A. conceived the study. P.P., O.H. and O.A. participated in study design. J.T., M.B.M., M.H. and P.P. were responsible for data acquisition. O.G. analyzed the data. P.P., O.G., O.A. and O.H. interpreted the data. P.P. drafted the manuscript. P.P., J.T., O.G., O.A., M.B.M., M.H. and O.H. revised the manuscript critically. All authors read and approved the final version of the manuscript.

Additional Information
Competing Interests: Ove Andersen invented a patent concerning suPAR and risk stratification. Copenhagen University Hospital Hvidovre, Denmark, owns the patent, which is licensed to ViroGates A/S. ViroGates A/S produces the suPARnostic assay used for suPAR analysis in this study. All other authors report no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019